Results 221 to 230 of about 128,389 (322)

The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase [PDF]

, 2000
Ryan P. Million, Richard A. Van Etten
openalex   +1 more source

A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia

Science Translational Medicine, 2014
Leyuan Ma, Y. Shan, R. Bai, Liting Xue, C. Eide, Jianhong Ou, L. Zhu, L. Hutchinson, J. Černý, H. Khoury, Z. Sheng, B. Druker, Shaoguang Li, Michael R. Green   +13 more
semanticscholar   +1 more source

PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation. [PDF]

Mol Cancer
Yang K, Fu K, Zhang H, Wang X, To KKW, Yang C, Wang F, Chen ZS, Fu L.   +8 more
europepmc   +1 more source

Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A. [PDF]

J Cancer, 2023
Xu Y, Wang Z, Zhang L, Gao C, Li F, Li X, Ke Y, Liu HM, Hu Z, Wei L, Chen ZS.   +10 more
europepmc   +1 more source

BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism [see comments]

, 1995
Jl. Vaerman, C. Lammineur, P Moureau, Philippe Lewalle, F. Deldime, Marta Blumenfeld, P. Martiat   +6 more
openalex   +1 more source

Ontogeny of natural killer cells and T cells by analysis of BCR–ABL rearrangement from patients with chronic myelogenous leukaemia [PDF]

, 2000
Eun Kyung Cho, Dae Seog Heo, Jae Goo Seol, Eul‐Ju Seo, Hyun Sook, Eun Shil Kim, Young Yiul Lee, Byoung Kook Kim, Noe Kyeong Kim   +8 more
openalex   +1 more source

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Cancer, 2014
S. Soverini, C. De Benedittis, C. Papayannidis, S. Paolini, C. Venturi, I. Iacobucci, M. Luppi, P. Bresciani, M. Salvucci, D. Russo, S. Sica, E. Orlandi, T. Intermesoli, A. Gozzini, M. Bonifacio, G. Rigolin, F. Pane, M. Baccarani, M. Cavo, G. Martinelli   +19 more
semanticscholar   +1 more source

In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I. [PDF]

Molecules
Rocha KML, Nascimento ÉCM, de Jesus RCC, Martins JBL.   +3 more
europepmc   +1 more source

Are aberrant BCR–ABL transcripts more common than previously thought? [PDF]

, 2000
G. A. Wilson, Elisabeth Vandenberghe, Rebecca C. Pollitt, Douglas C. Rees, Anne Goodeve, I. R. Peake, John T. Reilly   +6 more
openalex   +1 more source

Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN. [PDF]

J Nanobiotechnology
Sun Y, Wang Y, Liu C, Huang Y, Long Q, Ju C, Zhang C, Chen Y.   +7 more
europepmc   +1 more source